CNTX - NASDAQ
Context Therapeutics Inc.
$2.05
-15%Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
At a Glance
Live SnapshotNo Revenue Data
CNTX has not reported any revenue values in the available annual periods.
Context Therapeutics Inc. Profit Bridge
Profitability Analysis
Context Therapeutics Inc. Income Statement
CNTX • NASDAQ
| Context Therapeutics Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
GROSS PROFIT | |||||||
(124.7K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-124.7K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | |||||||
(39.7M) | (29.9M) | (25.1M) | (15.4M) | (10.5M) | (2.6M) | (5.4M) | |
(7.8M) | (7.2M) | (7.3M) | (7.8M) | (3.6M) | (930.7K) | (3M) | |
(31.9M) | (22.7M) | (17.8M) | (7.1M) | (3.8M) | (1.6M) | (2.4M) | |
-39.7M | -29.9M | -25.1M | -15.4M | -10.5M | -2.6M | -5.4M | |
PRE-TAX INCOME | |||||||
(0.0) | (0.0) | (0.0) | (547.3K) | (64.2K) | (661.2K) | (1.1M) | |
3.4M | 3.2M | 1.2M | 0.0 | -64.2K | -661K | -1.1M | |
(0.0) | (0.0) | (0.0) | (500K) | (3.1M) | (0.0) | (0.0) | |
3.6M | 3.2M | 1.1M | 545.3K | 68.9K | 9.2M | -1M | |
-36.1M | -26.7M | -24M | -14.8M | -10.5M | 6.6M | -6.4M | |
NET INCOME | |||||||
-36.1M | -26.7M | -24M | -14.8M | -10.5M | 6.6M | -6.4M |
SEC Filings
CNTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | April 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 23, 2026 | March 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 13, 2026 | March 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 |
Related Guides
Continue your CNTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.